Literature DB >> 16940456

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

Ricardo Azziz1, Enrico Carmina, Didier Dewailly, Evanthia Diamanti-Kandarakis, Hector F Escobar-Morreale, Walter Futterweit, Onno E Janssen, Richard S Legro, Robert J Norman, Ann E Taylor, Selma F Witchel.   

Abstract

OBJECTIVE: The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research. PARTICIPANTS: Participants included expert investigators in the field. EVIDENCE: Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. CONSENSUS PROCESS: The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by the AES Board of Directors. No section was finalized until all members were satisfied with the contents and minority opinions noted. Statements that were not supported by peer-reviewed evidence were not included.
CONCLUSIONS: Based on the available data, it is the view of the AES Task Force on the Phenotype of PCOS that there should be acceptance of the original 1990 National Institutes of Health criteria with some modifications, taking into consideration the concerns expressed in the proceedings of the 2003 Rotterdam conference. A principal conclusion was that PCOS should be first considered a disorder of androgen excess or hyperandrogenism, although a minority considered the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism but recognized that more data are required before validating this supposition. Finally, the task force recognized, and fully expects, that the definition of this syndrome will evolve over time to incorporate new research findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940456     DOI: 10.1210/jc.2006-0178

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  392 in total

Review 1.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

Review 2.  Metabolic syndrome, androgens, and hypertension.

Authors:  Mohadetheh Moulana; Roberta Lima; Jane F Reckelhoff
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

3.  Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust.

Authors:  Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2010-12       Impact factor: 5.958

4.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

5.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

6.  Sex and gender differences in cardiovascular, renal and metabolic diseases.

Authors:  Jane F Reckelhoff; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

7.  Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome.

Authors:  Soledad Henríquez; Paulina Kohen; Xia Xu; Claudio Villarroel; Alex Muñoz; Ana Godoy; Jerome F Strauss; Luigi Devoto
Journal:  Hum Reprod       Date:  2020-07-01       Impact factor: 6.918

8.  Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.

Authors:  Nina M Clark; Amanda J Podolski; Eric D Brooks; Donna R Chizen; Roger A Pierson; Denis C Lehotay; Marla E Lujan
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

9.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

10.  Prenatal testosterone exposure induces hypertension in adult females via androgen receptor-dependent protein kinase Cδ-mediated mechanism.

Authors:  Chellakkan S Blesson; Vijayakumar Chinnathambi; Gary D Hankins; Chandra Yallampalli; Kunju Sathishkumar
Journal:  Hypertension       Date:  2014-12-08       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.